Dianthus Therapeutics Investor Relations Material
Latest events
M&A Announcement
Dianthus Therapeutics
Access the full event backlog
Slides, Transcripts, and Reports from 9,000+ public companies
Latest reports from Dianthus Therapeutics Inc
Access all reports
Dianthus Therapeutics Inc., operating under the ticker DNTH, is a clinical-stage biotechnology company based in New York, New York. The company focuses on designing, developing, and delivering innovative monoclonal antibodies intended for the treatment of severe autoimmune and inflammatory diseases. Their key developmental product is DNTH103, currently in clinical trials, targeted at conditions such as generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. The company is headquartered in New York, NY, and its shares are listed on the NASDAQ.
Key slides for Dianthus Therapeutics Inc
Corporate Presentation
Dianthus Therapeutics Inc
Corporate Presentation
Dianthus Therapeutics Inc
Latest articles
The Brunello Cucinelli Story: Combining Elegance and Ethics
Explore the success of Brunello Cucinelli's unique blend of luxury craftsmanship and ethical business.
14 May 2024
Amazon's Most Notable Acquisitions Since Inception
Explore Amazon's most impactful acquisitions, from IMDb and Zappos to Whole Foods and MGM, and how these have diversified its business.
13 May 2024
Adidas vs Puma: The Story of the Dassler Brothers
An in-depth article outlining the story of the Dassler brothers, their feud with one another, and the history of Puma and Adidas.
10 May 2024
Ticker symbol
Country
đșđž United States